Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

İ. Karadogan



Author of

  • +

    P3.09 - Poster Session 3 - Combined Modality (ID 214)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P3.09-014 - Concurrent chemoradiotherapy for patients with unresectable stage III non-small cell lung carcinoma; A real-life experience (ID 2220)

      09:30 - 09:30  |  Author(s): İ. Karadogan

      • Abstract

      Background
      Investigators from the Hoosier Oncology Group reported that there was no survival advantage but significant toxicity from the addition of docetaxel consolidation to immediate radiation and concurrent cisplatin (P)–etoposide (E) for treatment in patients with unresectable stage III non-small-cell lung carcinoma (NSCLC). Concurrent chemoradiotherapy alone is standard treatment for fit patients in this group. The aim of this prospective study is to investigate the survival rates of standard treatment for these patients in a real-life.

      Methods
      Eligible patients had unresectable stage IIIA or IIIB NSCLC, baseline performance status of 0 to 1, less than 5% weight loss and adequate organ function. Patients received P 50 mg/m2 intravenously (IV) on days 1, 8, 29, and 36 and E 50 mg/m2 IV on days 1-5 and 29-33 concurrently with chest XRT to 63.00 Gy (1.8 Gy per fraction and 5 fractions per week).

      Results
      From January 2008 until December 2010, 59 patients were entered into the trial, 57 were evaluated. Patient characteristics were as follows: 94,7% male; median age, 56 years; 40,3% stage IIIA; and 59,7% stage IIIB; 64,9% squamous cell carcinoma, 17,5% adenocarcinoma. Objective response rate was 61,4% (complete response 19,3%). Grade 4 neutropenia was the most common toxicity (35,1%). 19,3% of patients experienced grade 2-3 pulmonary- late toxicity. 44 patients have died. 12,2% of patients had febrile neutropenia. One patient died due to renal toxicity. With a median follow-up time of 18 months, median progression-free survival (PFS) was 10,5 months, median overall survival (OS) was 18 months (11,7 to 24,2, 95% confidence interval), and two-, 3- and 4-year OS rates were 36,1%, 23,2%, and 16,9%, respectively. Two-, 3- and 4-year PFS rates were 17,4%, 13,2%, and 9,9%, respectively.

      Conclusion
      The survival rates in real-life studies as the current study can be expected to be mildly shorter than those in controlled clinical trials.